Clinical Trial Update: QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.002 trial evaluating N-803 in combination with Rituximab for relapsed/refractory indolent B-cell non-Hodgkin lymphoma has been terminated; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• N-803
• Rituximab (rituximab)

Snippet

Sponsor: Altor BioScience | Conditions: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-03